Modelling Drug-Target Binding Affinity using a BERT based Graph Neural Network

Mark Lennox¹, Neil Robertson², Barry Devereux³

Abstract—Understanding the interactions between novel drugs and target proteins is fundamentally important in disease research as discovering drug-protein interactions can be an exceptionally time-consuming and expensive process. Alternatively, this process can be simulated using modern deep learning methods that have the potential of utilising vast quantities of data to reduce the cost and time required to provide accurate predictions. We seek to leverage a set of BERT-style models that have been pre-trained on vast quantities of both protein and drug data. The encodings produced by each model are then utilised as node representations for a graph convolutional neural network, which in turn are used to model the interactions without the need to simultaneously fine-tune both protein and drug BERT models to the task. We evaluate the performance of our approach on two drug-target interaction datasets that were previously used as benchmarks in recent work.

Our results significantly improve upon a vanilla BERT baseline approach as well as the former state-of-the-art methods for each task dataset. Our approach builds upon past work in two key areas; firstly, we take full advantage of two large pre-trained BERT models that provide improved representations of task-relevant properties of both drugs and proteins. Secondly, inspired by work in natural language processing that investigates how linguistic structure is represented in such models, we perform interpretability analyses that allow us to locate functionally-relevant areas of interest within each drug and protein. By modelling the drug-target interactions as a graph as opposed to a set of isolated interactions, we demonstrate the benefits of combining large pre-trained models and a graph neural network to make state-of-the-art predictions on drug-target binding affinity.

I. INTRODUCTION

In recent years, deep learning has been used to model Drug-Target Interactions (DTIs) as it is ideally suited to handle large datasets without requiring feature engineering. By using deep learning to map out the drug-target landscape, one can quickly identify the proteins that are targeted by each drug – thereby accelerating drug discovery during clinical trials [33]. Initial applications of machine learning models posed this as a classification problem due to the variability between each interaction pair [3, 5, 25]. However, these early approaches do not provide enough information about the actual binding affinity value, which is troublesome when one seeks to learn the potency of a particular drug-target pair. Deep learning now plays an important role in determining patterns in complex drug-target systems. Applications of deep learning are becoming ubiquitous in drug-drug interaction modelling [32, 22], as well as forming predictions for protein-protein interactions [39, 28, 42], and the identification novel drug-target interactions [43, 45, 12, 16, 24].

In recent work, the focus has moved away from developing classification models. Instead, the drug-target identification problem has been formulated as a regression task that requires the model to predict the binding affinity value directly. Building a regression model has the potential to rank therapeutic drugs, which makes it more practical at identifying optimal compounds when a broad set of drugs are being analysed. These measured affinity values may include measurements such as dissociation constant ($K_d$), inhibition constant ($K_i$) or the half-maximal inhibitory concentration ($IC_{50}$).

In this paper, we will consider a BERT (Bidirectional Encoder Representations from Transformers) [10, 31] model, and a RoBERTa (Robustly Optimized BERT Pretraining Approach) [23] model that have been pre-trained on a large corpus of protein and drug data respectfully. During training, both models are used to provide node embeddings to the graph convolutional neural network (GCN) that is applied to model the interactions between the drug-target pairs. Our approach improves upon past work in two key areas; firstly, our method capitalises on two pre-trained BERT style networks, which provide robust embeddings for each drug and protein. These models can also be used to visualise the critical areas of interest within each drug-target pair. Such insights will benefit the field of computational biology as it becomes easier for the end-user to distil the knowledge from these models. Secondly, our method implements a GCN to model the interaction between individual pairs as opposed to past work that use a simple multilayer perceptron (MLP) to produce a prediction for the binding affinity value of each interaction.

In most cases, the total number of unique drugs and proteins tested during these experiments is limited, which does not provide a complete depiction of how a particular drug or target protein might operate under the same experimental conditions. We seek to address these issues through the use of pre-training and graph

---

*This work was not supported by any organization
¹EEECS, Queen’s University Belfast, mlennox05@qub.ac.uk
²EEECS, Queen’s University Belfast, n.robertson@qub.ac.uk
³EEECS, Queen’s University Belfast, b.devereux@qub.ac.uk
neural networks. End-to-end, our approach will be able to encode any drug-protein even if it is not present within the original datasets. By implementing this style of modelling our approach will be able to analyse and determine the essential features within each protein and drug sequence without causing the models to overfit to the limited number of labelled examples observed during training.

II. RELATED WORK

Previous machine learning methods relied on scoring functions, and a series of feature-engineered steps to transform the original drug-protein pair before producing a final prediction [2, 21, 34]. These approaches did not generalise well, as the machine learning models were optimised on a feature set engineered from only on a few observations. This limited scope provided less information about the raw interaction between the drug and the protein [13]. Examples include Kronecker Regularised Least Squares (Kron-RLS) [26] algorithm that utilised drug similarity information and a Smith-Waterman similarity representation [37] of each target protein to model interaction values by formulating it as a regression problem [37]. This kernel approach performed well, given its lack of complexity, which in turn stopped the model from overfitting during training. Later, He et al. designed a gradient boosting machine learning model [6] that was trained using network-based features from the observed drugs, targets and drug-target interactions from each dataset [16]. The training data was based on the drugs and targets, which formed the nodes of the graph, while the binding affinity values represented the edges. The Simboost algorithm was a significant jump from the Kron-RLS as it included a far more extensive and rigorous feature set, while also utilising a more sophisticated machine learning algorithm. However, both methods share the same constraint as they are only capable of modelling a summarisation of the raw data available for the drug-target interaction.

Recent work in the subfields of natural language processing (NLP) [29, 30, 10], and computer vision [20, 41, 38], has produced state-of-the-art results using deep learning approaches, and have recently revealed the value of pre-training large train models before tacking specific tasks. One of the main drawbacks to applying deep learning is the sacrifice of interpretability, as it becomes increasingly challenging to distil the knowledge of the model. Öztürk et al. designed a deep learning model for a set of DTI regression tasks that aimed to predict the binding affinity scores by utilising a set of convolutional neural networks (CNN) [24]. The proposed model was comprised of two individual three-layer CNNs that were adopted to encode the drug (i.e. SMILES strings) and target (i.e. protein sequences) respectively. The final features produced by each CNN were then max pooled and concatenated together before finally being passed through a multi-layer perceptron (MLP) to form a prediction for the binding affinity. Since the DeepDTA model incorporates CNN models to encode both the drug and the protein, it could only capture local dependencies within the SMILES strings and protein sequences.

Later, Shin et al. improved upon the DeepDTA model by replacing the drug CNN component with a pre-trained character transformer, that unified both transformer and convolutional neural networks [36]. The drug transformer was pre-trained using the PubChem database and was a clear improvement over a CNN as it was better at capturing long-range dependencies in the drug sequence. Such a characteristic is vital to model intermolecular interactions properly, as a deep learning model should be able to incorporate all the information about the structure of both the drug and the protein. However, the Shin et al. model still included a set of convolutional layers designed to extract features from the protein, and therefore suffered at accurately modelling the complete sequence of amino acids [36]. It should be noted that the transformer within the Shin et al. model required further fine-tuning to each interaction dataset before it could produce better results over the DeepDTA model [36].

Graph convolutional neural networks (GCNs) have also been used to encode the molecular graph, whereby the atoms are the nodes, and the bonds are the edges of the graph. Duvenaud et al. [11] implemented a GCN model to replicate circular fingerprints, which could extract relevant molecular features. Kearnes et al. [18] likewise presented a molecular graph convolutional model for learning small molecules. Coley et al. [8] used a GCN based approach to model the interactions between organic compounds to predict the final products. As an example of white-box deep learning, Kearnes et al. were able to gain insight and derive knowledge from the model’s predictions, which was later validated by experts [18]. Although the model in [8] was tailored to modelling drug reactions, it could be modified to integrate target protein information so that the most active drugs can be determined. These applications display the potential for future applications of deep learning within the virtual screening process.

III. MATERIALS AND METHODS

The modelling scheme used in this paper is outlined in Figure 1. Firstly each drug-protein pair is encoded into a vector representation by the pre-trained BERT and RoBERTa models. Our work improves upon past work by employing both of these state-of-the-art pre-trained models to provide robust representations for each drug and protein. The protein BERT model [10] was initially pre-trained and published by Rao et al. [31] with masked-token prediction of protein sequences available in the Pfam database [14]. The protein BERT model consisted of twelve-layers with a hidden size of 512 units and 12 attention heads. Each protein is encoded using a standard variable encoding scheme with
the complete vocabulary containing a total of thirty characters, including the special characters.

The drug RoBERTa model [23] was initially pre-trained by Chithrananda et al. [7] on 250,000 Simplified Molecular Input Line Entry System (SMILES) strings from the ZINC15 database of drug-like molecules [17], again it was pre-trained using masked-token prediction [7]. From the raw SMILES strings, the drugs were tokenised using a Byte-Pair Encoder (BPE), via the Huggingface tokeniser library [44], which is one of the most commonly applied subword encoding algorithms in natural language processing. Subword algorithms such as BPE can decompose rare words into frequently occurring subwords, which allows DNNs to model large vocabularies without hindering the model’s performance with out-of-vocabulary words. In our context, the subword encoding algorithm breaks the SMILES string into commonly occurring subsequences, and it is then able to find the most optimal vocabulary by iteratively merging symbols within the original SMILES string until the best segmentations was determined [35]. A set of additional tokens were also included within this vocabulary (i.e. to denote special tokens for unknown characters, padding, separation and masked characters) such as to avoid unknown tokens during the pre-training stage.

A. Modelling Scheme

As in previous work [16, 24], we will model the drug-target interaction as a regression task, whereby the model must produce predictions of the binding affinity scores. As mentioned above, our approach adopts a pair of pre-trained BERT models that contain six and twelve layers for the drug and protein model respectively. In both models, these layers are then followed by a final average pooling layer to produce a vector representation for each drug and protein (Figure 1, step 1).

In addition to the pre-trained BERT models, our approach includes graph convolutional layers (GCN) layers. Unlike past examples, we do not truncate either drug or protein when producing the final encodings. This will allow the graph neural network to learn a complete representation of each drug and protein, and thereby avoid training our algorithm with excessive amounts of padding. Once the model has collected local features based on the original BERT embeddings followed by the output of each of the GCN layers, these final features are then concatenated once more to form the drug-protein interaction pairs (Figure 1, step 2). Residual connections are employed between each GCN layer to improve training and the overall performance of the model. These interaction features are then passed through a set of dense layers to reduce the final interaction features into a prediction for the binding affinity scores (Figure 1, step 3). Mean squared error (MSE) is used as a loss function as we optimise our model via the Adam optimisation algorithm [19], with the default learning rate of 0.001. Once the network has been suitably trained, it can then encode each drug-protein pair and analyse how the observed interactions dictate the affinity values.

B. Tasks

Following [24], our approach was evaluated on two separate benchmark datasets, the Davis kinase dataset [9] and the KIBA dataset [40], as summarised in Table I. For both datasets, the drugs were represented in the SMILES string format and were downloaded using their individual PubChem CIDs to query the Pubchem compound database [4]. For the protein sequences, the accession number of each protein was used to locate and extract the protein sequence from the UniProt protein database [1]. The Davis dataset includes interactions between a subset of selectivity assays from a kinase

<table>
<thead>
<tr>
<th></th>
<th>Proteins</th>
<th>Drugs</th>
<th>Interactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Davis (K_d)</td>
<td>442</td>
<td>68</td>
<td>30,056</td>
</tr>
<tr>
<td>KIBA</td>
<td>229</td>
<td>2111</td>
<td>118,254</td>
</tr>
</tbody>
</table>

TABLE I: Summary of the two downstream tasks (Adapted from [24]).
TABLE II: Results for the two downstream tasks.

<table>
<thead>
<tr>
<th>Dataset</th>
<th>Method</th>
<th>MSE (std)</th>
<th>CI (std)</th>
<th>$r_m^2$ (std)</th>
<th>AUPR (std)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Davis</td>
<td>BERT-GCN (Ours)</td>
<td>0.199 (0.003)</td>
<td>0.896 (0.002)</td>
<td>0.741 (0.002)</td>
<td>0.806 (0.007)</td>
</tr>
<tr>
<td></td>
<td>BERT-MLP (Ours)</td>
<td>0.311 (0.009)</td>
<td>0.862 (0.004)</td>
<td>0.589 (0.022)</td>
<td>0.721 (0.009)</td>
</tr>
<tr>
<td></td>
<td>MT-DTI [36]</td>
<td>0.245</td>
<td>0.887 (0.003)</td>
<td>0.665 (0.014)</td>
<td>0.730 (0.014)</td>
</tr>
<tr>
<td></td>
<td>DeepDTA [24]</td>
<td>0.261</td>
<td>0.878 (0.004)</td>
<td>0.630 (0.017)</td>
<td>0.714 (0.010)</td>
</tr>
<tr>
<td></td>
<td>SimBoost [16]</td>
<td>0.282</td>
<td>0.872 (0.002)</td>
<td>0.644 (0.006)</td>
<td>0.709 (0.008)</td>
</tr>
<tr>
<td></td>
<td>KronRLS [27]</td>
<td>0.379</td>
<td>0.871 (0.001)</td>
<td>0.661 (0.010)</td>
<td></td>
</tr>
<tr>
<td>KiBa</td>
<td>BERT-GCN (Ours)</td>
<td>0.139 (0.001)</td>
<td>0.888 (0.001)</td>
<td>0.761 (0.009)</td>
<td>0.838 (0.003)</td>
</tr>
<tr>
<td></td>
<td>BERT-MLP (Ours)</td>
<td>0.282 (0.005)</td>
<td>0.803 (0.002)</td>
<td>0.580 (0.008)</td>
<td>0.748 (0.008)</td>
</tr>
<tr>
<td></td>
<td>MT-DTI [36]</td>
<td>0.152</td>
<td>0.882 (0.001)</td>
<td>0.738 (0.006)</td>
<td>0.837 (0.003)</td>
</tr>
<tr>
<td></td>
<td>DeepDTA [24]</td>
<td>0.194</td>
<td>0.863 (0.002)</td>
<td>0.673 (0.009)</td>
<td>0.788 (0.004)</td>
</tr>
<tr>
<td></td>
<td>SimBoost [16]</td>
<td>0.222</td>
<td>0.836 (0.001)</td>
<td>0.629 (0.007)</td>
<td>0.760 (0.003)</td>
</tr>
<tr>
<td></td>
<td>KronRLS [27]</td>
<td>0.411</td>
<td>0.782 (0.001)</td>
<td>0.342 (0.001)</td>
<td>0.635 (0.004)</td>
</tr>
</tbody>
</table>

protein family and a set of inhibitors, which were measured using the dissociation constant ($K_d$) across 442 unique proteins and 68 unique drugs. As in previous work [16, 24], we use the log-transform of the $K_d$ values. As the majority of the Davis dataset is inactive, it leads to a highly unbalanced distribution as a majority of the interactions either have such a low binding affinity value (i.e. $K_d > 10,000$ nM) or was not observed in the primary screen [27].

The KIBA dataset was filtered during the Simboost study to yield a total of 229 unique proteins and 2,111 unique drugs [16]. This dataset was designed to cover the bioactivity of specific kinase inhibitors from various studies, which were combined to include interactions based on $K_i$, $K_d$ and $IC_{50}$ values [40]. For more information on how the KIBA scores were generated, please see citations [16].

The value of using a GCN approach to model the drug-target interactions as opposed to fine-tuning both BERT models simultaneously is realised when we consider the typical sequence length of either drug or protein. In the Davis dataset, the maximum drug length is 103 (average: 64), and a maximum protein length is 2,549 (average: 788). In the KIBA dataset, the maximum drug length is 590 (average: 58), and the maximum protein length is 4,128 (average: 728). To fine-tune BERT models of this size would become very computationally expensive as a considerable amount of padding would be required during this fine-tuning stage, which would increase the time required to optimise both models to the interaction task.

IV. RESULTS AND DISCUSSION

To properly evaluate the predictive performance of our model, we calculated the mean square error (MSE), Concordance Index (CI) [15], $r_m^2$ index, and Area Under Precision-Recall (AUPR) (i.e. utilised for binary predictions) scores for all predictions, as shown in Table II. To calculate the AUPR scores for either dataset, the binding activity values were binarised by selecting a particular threshold value. Following previous evaluation using these datasets for the SimBoost and DeepDTA models [16, 24], a threshold value of 7 was used for binarising $pK_d$ values in the Davis dataset and a value of 12.1 was used for the KIBA dataset.

For a fair comparison to the previous models, we also performed a five-fold cross-validation procedure using only the training data to validate the performance of our approach. We then averaged the test scores across all five folds on the same external test set as was used for previous models. Table II also includes the standard deviation for each metric across all five-folds for both datasets. In some cases, the standard deviation is missing from previous models as it was not provided in the literature. To provide an unbiased final measure of performance in each dataset, we evaluated our approach on the same independent test set that was used in previous studies. We then tested our BERT-GCN approach against a vanilla BERT approach, which removes the GCN layers and only uses a set of fully connected layers to model the interaction (MLP-BERT). In addition to the DeepDTA and SimBoost models, we also compared our model to the KronRLS algorithm, which like SimBoost is based on employing similarity matrices for both drugs and proteins as input features to the model [27]. We also examined the MT-DTI approach that learned only drug sequence representation with a BERT block and retained a similar CNN to encode each protein, much like the DeepDTA model [36].

When the vanilla BERT encodings were used as inputs to an MLP, there appeared to be no performance benefits from using these large pre-trained networks. This result is unsurprising as neither the protein BERT model nor the drug RoBERTa model was fine-tuned simultaneously to model drug-protein interactions. As mentioned, given that protein and drug sequences can be considerably long, it would have been far too computationally expensive to run both models to perform fine-tuning. However, to capitalise on the pre-training that was conducted for both BERT networks, we were motivated to find a solution that used both pre-trained models but was also computationally feasible to the end-user. To improve upon the previous pre-trained results, we tested the combination of using these pre-trained models in coordination with a set of GCN layers, which would then model the interactions between the proteins and...
drugs. This method outperformed all baseline methods with the lowest average MSE scores for both the Davis and Kiba datasets and likewise achieving the highest CI, $r^2_m$ and AUPR scores on both datasets.

V. Conclusions

In this paper, we proposed a deep learning model that is capable of accurately predicting drug-target binding affinity values. By adopting a pair of pre-trained BERT models along with and a graph convolutional neural network, and without manually engineering any features about the biochemistry of these interactions, this model was able to encode the sequence representations of both drugs and targets to produce state-of-the-art results. We evaluated our approach on two benchmark datasets and compared our model to previous state-of-the-art machine learning and deep learning baselines. Our results indicated that the predefined features produced by the BERT models alone could not sufficiently be applied to represent a drug-target interaction. However, when additional GCN layers were used to learn each interaction as a component of a more extensive network, the performance increased significantly compared to baseline methodologies for both datasets. Without the need to directly fine-tune both BERT models to the DTI task, we were able to improve performance by using a graph neural network to overcome this computationally expensive process.

This study provides a method that utilises state-of-the-art pre-trained models to produce the most accurate interaction network for binding affinity prediction. Our approach not only saves time and computational resources with regards to training, but it also provides the best overall performance when compared to past state-of-the-art approaches that required additional feature engineering. In future work, we aim to utilise better pre-trained models that apply subword encoding algorithms during pre-training, along with building an interpretable graph neural network system that operates on these pre-trained encodings to provide improved predictions for novel interactions.

References


